Dr Sam Jackson

Position

Programme Manager – Disease models, efficacy and safety pharmacology

LinkedIn

http://uk.linkedin.com/in/samueljjackson/

Email address

sam.jackson@nc3rs.org.uk


Sam leads our programmes on disease models, efficacy and safety pharmacology. He is a member of the Science and Technology Group.

View Sam's Office-led projects

NC3Rs publications

Jackson SJ, Authier S, Brohmann H et al. (2019) Neurofunctional test batteries in safety pharmacology - Current and emerging considerations for the drug development process. J Pharmacol Toxicol Methods 100:106602. doi: 10.1016/j.vascn.2019.106602.

Jackson SJ, Prior H and Holmes A (2018). The use of human tissue in safety assessment. J Pharmacol Toxicol Methods 93:29-34. doi: 10.1016/j.vascn.2018.05.003.

Jackson SJ and Thomas GJ (2017). Human tissue models in cancer research: looking beyond the mouse. Dis Model Mech 10 (8): 939-942. doi: 10.1242/dmm.031260.

Jackson SJ et al. (2017). Does age matter? The impact of rodent age on study outcomes. Lab anim 51 (2): 160-169. doi: 10.1177/0023677216653984.

Mead AN, Amouzadeh H, Chapman K et al. (2016). Assessing the predictive value of the rodent neurofunctional assessment for commonly reported adverse events in phase I clinical trials. Regul Toxicol Pharmacol 80:348-57. doi:10.1016/j.yrtph.2016.05.002.

For additional publications, please see Sam's Google Scholar or ResearchGate profile.

Qualifications

PhD, Neurobiology
University College London, 2000-2004
Cannabinoids and neuroprotection in in vivo and in vitro models of multiple sclerosis.
 
MRes, Neuroscience
University of Manchester, 1999-2000